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Background. Metformin, the most widely administered diabetes drug, has been proposed as a candidate adjunctive host-di-
rected therapy for tuberculosis, but little is known about its effects on human host responses to Mycobacterium tuberculosis.
Methods. We investigated in vitro and in vivo effects of metformin in humans.
Results. Metformin added to peripheral blood mononuclear cells from healthy volunteers enhanced in vitro cellular metabolism 
while inhibiting the mammalian target of rapamycin targets p70S6K and 4EBP1, with decreased cytokine production and cellular 
proliferation and increased phagocytosis activity. Metformin administered to healthy human volunteers led to significant downreg-
ulation of genes involved in oxidative phosphorylation, mammalian target of rapamycin signaling, and type I interferon response 
pathways, particularly following stimulation with M. tuberculosis, and upregulation of genes involved in phagocytosis and reactive 
oxygen species production was increased. These in vivo effects were accompanied by a metformin-induced shift in myeloid cells 
from classical to nonclassical monocytes. At a functional level, metformin lowered ex vivo production of tumor necrosis factor α, 
interferon γ, and interleukin 1β but increased phagocytosis activity and reactive oxygen species production.
Conclusion. Metformin has a range of potentially beneficial effects on cellular metabolism, immune function, and gene tran-
scription involved in innate host responses to M. tuberculosis.
Keywords. Metformin; tuberculosis; host-directed therapy; antimycobacterial mechanisms, gene transcription.
Diabetes increases susceptibility to tuberculosis [1] and worsens 
tuberculosis outcome [2]. The mechanisms behind this increase 
in susceptibility are unclear, and a role for diabetes drugs could 
be envisioned. In particular, the diabetes drug metformin has 
antiinflammatory effects and inhibits pathways such as mam-
malian target of rapamycin (mTOR) signaling, which are im-
portant in the host defense against Mycobacterium tuberculosis 
[3]. Nonetheless, metformin has been demonstrated to enhance 
mycobacterial clearance in mice [4] and is associated with lower 
rates of M. tuberculosis infection in humans [5]. Adding to that, 
the use of metformin in humans has been associated with a 
plethora of positive effects, potentially linked to glycemic con-
trol, such as a reduced risk of developing active tuberculosis [6, 
7], a lower tuberculosis mortality rate [8], an increased tubercu-
losis treatment success rate, a reduced tuberculosis relapse rate 
[9], and enhanced culture conversion [9, 10].
Proposed mechanisms for metformin’s beneficial effects in-
clude an increase in mitochondrial reactive oxygen species 
(mROS) and enhanced killing of M.  tuberculosis, but none 
of these have been investigated in humans. Importantly, the 
mechanism of action behind metformin’s effects are not clearly 
defined, because metformin acts through several pathways, 
including mitochondrial complex I  inhibition; an increase in 
adenosine monophosphate (AMP)/adenosine triphosphate lev-
els, leading to increased AMP activated kinase (AMPK) signal-
ing; and decreased glucagon and mTOR signaling [11]. Last, it 
is challenging to study the effects of metformin in people living 
with diabetes, because characteristics of diabetes, such as hy-
perglycemia, dyslipidemia, vitamin D deficiency, and oxidative 
stress, may all affect immune responses to M. tuberculosis [12].
We therefore investigated the effects of metformin in humans 
without diabetes. We first characterized metformin’s effects on 
in vitro responses to M.  tuberculosis and then validated these 
findings in vivo in healthy volunteers, showing that metformin 
alters mTOR signaling, inhibits p38 and AKT, rewires the blood 
cellular landscape, and enhances anti–M. tuberculosis responses.
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METHODS
Healthy Volunteers and Functional Laboratory Assays
In the in vivo study, 11 healthy Dutch adults were given met-
formin in increasing doses, ending with a commonly used 
dose of 1000 mg twice daily. For all other in vitro experiments, 
blood specimens from healthy Dutch adults (estimated tuber-
culosis incidence, 1.5 cases/100  000) were subject to analysis 
in the presence or absence of metformin. Isolated peripheral 
blood mononuclear cells (PBMCs), CD14+ monocytes, or M1/
M2 macrophages were stimulated with M.  tuberculosis lysate 
for production of tumor necrosis factor α (TNF-α), interleukin 
1β (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), inter-
leukin 17A (IL-17A), interleukin 22, and interferon γ (IFN-γ). 
Proliferation of CD4+ T cells was measured by flow cytometry 
of carboxyfluorescein succinimidyl ester–labeled PBMCs stim-
ulated for 6  days with M.  tuberculosis lysate. Metabolic mea-
surements included lactate production in stored cell culture 
supernatants, the redox ratio of nicotinamide adenine dinu-
cleotide (oxidized; NAD+)/nicotinamide adenine dinucleotide 
(reduced; NADH) levels in cell lysates, glucose consumption, 
and mitochondrial mass and membrane potential. Activation 
of downstream mTOR target signaling was assessed by Western 
blot of phosphorylated (p)-AMPK, p-p70 S6K, p-4EBP1, p-P38, 
and p-AKT. Production of reactive oxygen species (ROS) was 
determined after incubation of whole-blood specimens or 
PBMCs with zymosan or M.  tuberculosis lysate, by measure-
ment of chemiluminescence after the addition of luminol. 
Phagocytosis was measured in PBMCs, using pHrodo Green 
Zymosan Bioparticles Conjugate and flow cytometry. M. tuber-
culosis infection was measured in PBMCs incubated with M. tu-
berculosis (H37Rv) at a multiplicity of infection (MOI) of 5 for 
3 hours, lysed, and cultured on Middlebrook 7H11. Cellular vi-
ability of PBMCs was assessed by flow cytometry of Annexin 
V–FITC and propidium iodide–stained PBMCs.
Transcriptomics
RNA sequencing (RNAseq; GSE102678) analysis was per-
formed on participants’ samples before and after metformin 
administration, directly on ex vivo whole-blood specimens, 
and on isolated PBMCs following incubation with M. tubercu-
losis lysate. Libraries were prepared using stranded preparation 
reagents from Illumina and sequenced on a NextSeq500, gen-
erating approximately 36 million–45 million 43-bp paired-end 
reads per sample. Sequence files were aligned to the human ge-
nome, and aligned reads were counted. Differentially expressed 
genes were determined using the R package DESeq2, and gene 
set analyses were performed to determine how metformin af-
fected biological pathways in vivo and in the in vitro response to 
M. tuberculosis. Quantitative reverse transcription–polymerase 
chain reaction (qRT-PCR) analysis was performed to validate 
RNAseq and functional assay results.
CyTOF Marker Labeling, Data Acquisition, and Analysis
PMA and ionomycin stimulated PBMCs were stained with 
heavy-metal isotope–labeled antibodies (Supplementary Table 
1) [13], barcoded, and acquired on CyTOF 1 (Fluidigm). 
Samples were debarcoded using manual gating in FlowJo, and 
analysis of live CD14+/-CD16+/- monocytes was performed 
using the t-distributed stochastic neighbor embedding (tSNE) 
dimension reduction and Phenograph-based clustering algo-
rithm [14]. See the Supplementary Methods for details on mass 
cytometry and statistical analysis.
Statistics
All values are expressed as means ± standard errors of the mean 
of individual samples. Unless otherwise specified, data analysis 
was performed using the paired t test or the Wilcoxon signed 
rank test in GraphPad Prism software (GraphPad).
Study Approval
Written informed consent was received from participants 
prior to their inclusion in the study. Experiments were 
conducted according to the principles expressed in the 
Declaration of Helsinki. Ethical approval of studies performed 
in vitro (NL32357.091.10) and involving healthy volunteers 
(NL47793.091.14) was granted by the Arnhem-Nijmegen 
Ethical Committee. As validation, ethylenediaminetetraacetic 
acid–anticoagulated blood from 10 healthy young subjects 
who received metformin (500 mg on days 1 and 2, increasing 
to 1000 mg on days 3–8) was examined as part of a pharma-
cokinetic study (NL53534.091.15). The human RNAseq study 
was approved by the London School of Hygiene and Tropical 
Medicine Research Ethics Committee (11968).
RESULTS
Metformin Regulates Cellular Metabolism and Cytokine Production 
in Humans
We assessed the effects of metformin on glycolytic metabolism 
in human cells. When added to M.  tuberculosis lysate–stimu-
lated PBMCs from healthy individuals, metformin increased 
lactate production and glucose consumption (Figures 1A and 
1B) while decreasing the ratio of the NAD+ level to the NADH 
level (Figure 1C). At both therapeutic concentrations (ie, 
10–220 µM) and experimental concentrations [15], metformin 
showed clear effects on cytokine production. Depending on 
cell type, different concentrations of metformin significantly 
decreased M.  tuberculosis lysate–induced production of (1) 
TNF-α, IL-10, IFN-γ, and IL-17 by PBMCs (Figure 2A); (2) 
IL-1β, IL-6, and IL-10 by M1 and M2 monocyte-derived mac-
rophages (Figure 2B); and (3) TNF-α, IL-1β, and IL-10 by 
CD14+ monocytes (Supplementary Figure 1A). At a transcrip-
tional level, metformin inhibited expression of IL18, IL23P19, 
and TGFB1 (Figure 2C). The minimal effect of metformin on 
cellular proliferation (Figure 2D) is unlikely to account for the 
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strong effects on cytokine production (Figure 2E). Finally, al-
though findings were only suggestive rather than statistically 
significant, metformin also decreased the phosphorylation lev-
els of the downstream mTOR targets p-p70S6K and p-4EBP1, 
while increasing phosphorylation of its known molecular 
target, AMPK (Supplementary Figure 1B). Metformin at the 
doses tested also had no significant effect on cellular viability 
(Supplementary Figure 1C).
Transcriptional Profiling Reveals a Metformin-Related Gene Expression 
Signatures in Humans
Next, we investigated the in vivo effect of metformin. Healthy 
subjects received standard dose of metformin, and blood spec-
imens were collected at several time points before and after 
metformin intake (Figure 3A). As expected, the level of p-AMPK 
was increased in both unstimulated and M.  tuberculosis lysate–
stimulated PBMCs after metformin intake (Figure 3B–D and 
Supplementary Figure 2A). RNAseq analysis of whole-blood spec-
imens revealed that metformin intake had no significant effects 
on individual genes (Supplementary Figure 2B). Instead, a con-
sistent metformin-mediated effect was observed on combined 
sets of genes (Figure 3E), including significant downregulation of 
OXPHOS and ribosome pathways and significant upregulation 
of endocytosis/phagocytosis, MAPK, and chemokine signaling 
pathways.
In PBMCs, metformin intake led to differential expression 
of approximately 800 genes, both in unstimulated and M. tu-
berculosis lysate–stimulated cells (Supplementary Figure 2C). 
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Figure 1. Metformin alters the mammalian target of rapamycin (mTOR) signaling axis while maintaining glucose regulatory effects. A, C, and D, Lactate production (A), 
glucose consumption (C), and fold change in nicotinamide adenine dinucleotide (oxidized; NAD+)/nicotinamide adenine dinucleotide (reduced; NADH) levels (D) in peripheral 
blood mononuclear cells (PBMCs) stimulated with Mycobacterium tuberculosis lysate in the presence or absence of 1000 µM metformin for 24 hours, 48 hours, or 7 days. 
For panel A, data are from 2 individual experiments. For panels A–C, data are shown as means ± standard errors of the mean from 2–3 experiments and 6–9 donors. RPMI, 
Roswell Park Memorial Institute medium. *P < .05 and ** P < .01, by the Wilcoxon matched-pairs signed rank test.
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In unstimulated PBMCs, metformin intake led to upregula-
tion of genes involved in mitosis and downregulation of genes 
involved in OXPHOS, adipogenesis and myc targets (Figure 
3F). In M. tuberculosis–stimulated PBMCs, metformin intake 
led to suppression of genes involved in signaling of cytokines 
such as IFN-α, IFN-γ, and TNF-α, as well as genes involved 
in the OXPHOS and mTOR pathways (Figure 3F), all in 
line with the in vitro effects of metformin (Figures 1 and 2, 
respectively).
Cytokine Responses to M.  tuberculosis Are Suppressed by Metformin 
In Vivo
Each gene ontology (GO) group in the identified gene sets 
was investigated, and the “response to type 1 interferon” GO 
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Figure 2. Metformin affects the cytokine profile of human cells stimulated with Mycobacterium tuberculosis. A and B, Cytokine production from human peripheral blood 
mononuclear cells (PBMCs; A) and monocyte-derived M1 and M2 macrophages (B) stimulated with M. tuberculosis lysate, with or without 3–3000µM of metformin for 24 
hours (for tumor necrosis factor α [TNF-α], interleukin 6 [IL-6], interleukin 1β [IL-1β], and interleukin 10 [IL-10]) or 7 days (for interferon γ [IFN-γ], interleukin 17 [IL-17], and 
interleukin 22 [IL-22]). C, Cytokine gene expression in CD14+ monocytes stimulated with M. tuberculosis lysate with or without 3000 µM metformin after 4 hours (for inter-
leukin 18 [IL-18] and transforming growth factor β1 [TGF-β1]) or 24 hours (for interleukin 23p19 [IL-23p19] and interleukin 12p35 [IL-12p35]). D, Percentage CD4+ T-cell pro-
liferation in PBMCs stimulated with M. tuberculosis lysate in the presence or absence of 300 µM metformin for 6 days, using carboxyfluorescein succinimidyl ester labeling 
to track generations. E, Fold change in cytokine production by PBMCs stimulated with M. tuberculosis lysate with 3000 µM metformin, relative to stimulation in the absence 
of metformin. Values <1 indicate reduced cytokine production. This is indicated by projection toward the center of the radius. All data are means ± standard errors of the 
mean. For panels A–C and E, data are from 3 experiments and 6–13 donors. For panel D, data are from 4 experiments and 7 donors. *P < .05 and **P < .01, by the Wilcoxon 
matched-pairs signed rank test (for panels A–C) and the paired t test (for panel D).
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set showed the most markedly reduced expression in ex vivo 
M.  tuberculosis lysate–stimulated PBMCs from individuals 
taking metformin (Supplementary Figure 2D). Within this 
GO set, the expression of 8 genes (IFIT1, IFIT2, and IFIT3, 
which encode IFN-induced protein with tetratricopeptide 
repeats 1, 2, and 3, respectively; OAS1, OAS2, and OAS3, 
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Figure 3. Global effects of metformin in healthy human volunteers. A, Healthy volunteers (n = 11) received an increasing dose of metformin for 5 consecutive days. 
Blood specimens were collected twice before and several times after metformin treatment. B, Western blot analysis of p-AMPK in lysates of peripheral blood mononuclear 
cells (PBMCs) collected from healthy volunteers before and after metformin intake and stimulated for 2 hours with Roswell Park Memorial Institute medium (RPMI; −) or 
Mycobacterium tuberculosis lysate (+). Four representative donors are shown. C, Quantitative relative band intensity analysis of phospho-AMPK (p-AMPK) before (treatment 
day 0 [Td0]) and after (Td6) metformin treatment in samples stimulated with RPMI or M. tuberculosis lysate. Data are means ± standard errors of the mean for 8 donors. D, Fold 
change in p-AMPK levels before (Td0) and after (Td6) metformin treatment in samples stimulated with RPMI or M. tuberculosis lysate. Data for 8 donors are shown. *P < .05 
and **P < .01, by the paired t test. Western blot data are normalized to the loading control, actin. E, Gene set analysis of RNA sequencing data, showing Kyoto Encyclopedia 
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which encode 2′-5′-oligoadenylate synthase 1, 2, and 3, re-
spectively; MX1, which encodes MX dynamin-like GTPase 
1; and RSAD2, which encodes radical S-adenosyl methio-
nine domain containing 2)  was reduced >2-fold following 
metformin administration in cells stimulated with M. tuber-
culosis lysate for 4 hours (Figure 4A) and, to a lesser extent, 
after stimulation for 24 hours, as shown by qRT-PCR analysis 
(Figure 4A). Additionally, metformin intake led to a signifi-
cant decrease in TNF-α, IL-1β, IL-6, IFN-γ, and IL-17 release 
in response to M. tuberculosis lysate (Figure 4B), with effects 
on cytokine production up to 21 days after metformin intake. 
Collectively, our results indicate that metformin inhibits the 
M. tuberculosis–induced type 1 IFN response and inflamma-
tion in human PBMCs.
A
Volunteer 1 Volunteer 2 Volunteer 1 Volunteer 2
Td0 Td6 Td0 Td6
– + – + – + – +
Td0 Td6 Td0 Td6
– + – + – + – +
p-P38
Actin
Total 
p38
B
DC
E
p-AKT
Actin
p-4EBP1
p-p38/Total p38
0
2
4
6
8
RPMI
In
te
ns
ity
In
te
ns
ity
*
**
M. tuberculosis
lysate
F
1000
10 000
L
ev
el
, p
g/
m
L
TNF-α
**
*
*
2000
3000
4000
5000
L
ev
el
, p
g/
m
L
IL-1β
*
1000
10 000
100 000
L
ev
el
, p
g/
m
L
IL-6
**
0
100
200
300
400
L
ev
el
, p
g/
m
L
IL-10
0
2000
4000
6000
8000
10 000
L
ev
el
, p
g/
m
L
IFN-γ
**
0
50
100
150
L
ev
el
, p
g/
m
L
IL-17
*
0
1000
2000
3000
4000
L
ev
el
, p
g/
m
L
IL-22
*
.08
Td0 Td6 Td9 Td21 Td0 Td6 Td9 Td21 Td0 Td6 Td9 Td21
Td0 Td6 Td9 Td21 Td0 Td6 Td9 Td21 Td0 Td6 Td9 Td21 Td0 Td6 Td9 Td21
Td0
Td0
Td6
Td6
p-AKT/Actin
0.0
0.2
0.4
0.6
0.8
*
p-4EBP1/Actin
0.0
0.2
0.4
0.6
0.8
1.0
In
te
ns
ity
0
0 103 105
20
40
60
80
100
Pe
rc
en
ta
ge
 o
f m
ax
im
um
6000
5500
5000
4500
4000
M
T
 G
re
en
 (M
FI
)
C
D
14
+
 C
D
16
–  
M
on
oc
yt
es
RNASeq qRT-PCR
IFIT1
IFIT2
IFIT3
OAS1
OAS2
OAS3
MX1
RSAD2
*
*
*
*
*
*
*
*
**
*
*
*
*
**
**
– + – +
– – + +
4
0 0 2 42000 4000 6000
4 4 4
– + – +
– – + +
4 4 4 4
– + – +
– – + +
24 24 24 24
Metformin
M. tuberculosis lysate
incubation Time (h)
Transcript Count Normalized Expression (ΔΔCt)
Td0 Td6 Td0 Td6
RPMI M. tuberculosis
lysate
Td0 Td6 Td0 Td6
RPMI M. tuberculosis
lysate
Td0 Td6 Td0 Td6
MT Green
P  ≤ .04
Figure 4. Metformin intake in healthy volunteers affects cytokine production via p38 and AKT inhibition. A, Expression of 8 genes in the “response to type 1 interferon” 
Gene Ontology group among peripheral blood mononuclear cells (PBMCs) collected before and after in vivo metformin administration from healthy volunteers and stimulated 
with Mycobacterium tuberculosis lysate in vitro for 4 or 24 hours. Expression measured by RNA sequence (RNAseq) analysis (at 4 hours) and quantitative reverse transcrip-
tion–polymerase chain reaction (qRT-PCR) analysis (at 4 and 24 hours). B, Cytokine production from isolated PBMCs collected before and after metformin intake and stim-
ulated with M. tuberculosis lysate for 24 hours (for tumor necrosis factor α [TNF-α], interleukin 6 [IL-6], interleukin 1β [IL-1β], and interleukin 10 [IL-10]) or after 7 days (for 
interferon γ [IFN-γ], interleukin 17 [IL-17], or interleukin 22 [IL-22]) in the presence of 10% pooled human serum. C and D, Findings of Western blot analysis of phospho-p38 
(p-p38) and total p38 levels (C) and p-AKT and p-4EBP1 levels (D) in lysates of PBMCs collected from healthy volunteers before and after metformin intake and stimulated for 
2 hours in Roswell Park Memorial Institute medium (RPMI; −) or M. tuberculosis lysate (+). Data are representative of 4 of 8 evaluated donors from the trial. Western blot data 
are normalized to the loading control, actin. E, Fold change in p-p38/total p38 levels, p-AKT/actin levels, or p-4EBP1/actin levels in PBMCs collected before (treatment day 0 
[Td0]) versus those collected after (Td6) metformin treatment and stimulated with RPMI or M. tuberculosis lysate. F, Mitochondrial mass assessment in CD14+CD16- mono-
cytes. The left panel is overlay of data from before and after metformin treatment in a specimen from the same individual. The right panel should the median fluorescence 
intensity (MFI) yielded by MitoTracker Green (MT) in 3 samples. Gray, FMO control. *P < .05 and **P < .01, by the paired t test. Western blot data are mean values ± standard 
errors of the mean and are representative of 8 donors presented in panels C or D or Supplementary Figure 3A or 3B.
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Metformin Regulates the AKT-mTOR Pathway and Mitochondrial 
Metabolism in Humans
Because the MAPK, AKT, and mTOR pathways are known to 
strongly influence cytokine production, levels of p-P38 and 
total P38 (Figure 4C and Supplementary Figure 3A) and p-AKT 
and p-4EBP1 (Figure 4D and Supplementary Figure 3B) were 
measured in PBMCs before and after metformin intake. An 
overall decrease in the phosphorylation of all 3 targets was 
observed. Quantitative band intensity analysis showed that the 
ratio of the p-P38 level to the total P38 level, the level of p-AKT/
actin, and the level of p-4EBP1/actin were in most cases sig-
nificantly reduced because of metformin intake (Figure 4E). 
Supplementary Figure 3C–E demonstrate the effects on phos-
phorylation at an individual level. For further evidence, we ana-
lyzed the effect of metformin on the gene expression levels of 
these enzymes and found decreased expression of AKT2 (fitting 
with metformin’s role in homeostasis) and increased expression 
of PRKAB2 (which encodes a regulatory subunit of AMPK; 
Supplementary Figure 3F). Because AKT and mTOR are cen-
tral metabolic regulators [16, 17], we investigated the effects of 
metformin on mitochondrial mass (Supplementary Figure 4A). 
Metformin increased the mitochondrial mass of CD14+CD16- 
classical monocytes, as demonstrated by an increased 
Mitotracker green median fluorescence intensity (Figure 4F). 
This increase was not observed for CD14-CD16+ nonclassical 
monocytes (Supplementary Figure 4B). This highlights met-
formin-mediated alterations in mitochondrial functionality in 
CD14+CD16- classical monocytes, which may correlate with the 
antiinflammatory effect of metformin [18, 19].
Metformin Modulates the Peripheral Monocyte Landscape in Humans
Metformin intake altered the number and distribution of cir-
culating immune cells. In whole-blood specimens, metformin 
led to a transient increase in the total white blood cell (WBC) 
and neutrophil counts (Figure 5A) without altering the relative 
distribution of cell types (Figure 5B). In PBMCs, metformin 
increased the proportion of monocytes and decreased the pro-
portion of lymphocytes (Figure 5C).
To achieve a single-cell systems-level perspective of the effect 
of metformin on monocytes, PBMCs from blood specimens 
collected before (ie, on treatment day 0 [Td0]) and after (ie, 
on Td6) metformin intake were stimulated with phorbol ester 
and ionomycin, stained with a panel of 38 surface and intracel-
lular cytokine markers (Supplementary Table 1), and analyzed 
using CyTOF [20]. We first verified the panel antibodies for 
their binding to the PBMCs (Supplementary Figure 5) and then 
gated out the pure population of monocytes (CD3-CD19-CD56-
γδTCR-Vd1-VD2-CD57-CD161-CD14+/-CD16+/-) for analysis 
(Supplementary Figure 6). Analysis of monocytes by using tSNE 
in conjunction with a Phenograph-based clustering algorithm 
[14, 21] identified 12 distinct cell clusters with shared surface and 
intracellular marker expression characteristics (Figures 5D and 
5E). Based on the expression of CD14, CD16, and CCR2, the 12 
clusters were divided into 5 monocyte subsets (Figure 5E), illus-
trating significant heterogeneity among the classical and non-
classical monocyte populations in humans. Three of 12 clusters 
were found to be significantly enriched or depleted in samples 
from Td6, compared with samples from Td0. These differentiated 
clusters included the following diverse activated phenotypes: 
CD14hiCD16-MIP-1β+IL-2-TNFα- (cluster 2, downregulated), 
CD14hiCD16-MIP-1β+IL-2+TNFα- (cluster 10, downregulated), 
and CD14loCD16loMIP-1β+IL-2-TNFα+ (cluster 5, upregulated; 
Figure 5F). The accuracy of machine-learning automated gat-
ing when validated by manual gating showed that clusters 2 and 
10 were CD14hiCD16- and that cluster 5 was CD14loCD16mid 
(Supplementary Figure 7A). Furthermore, manual gating re-
vealed that only clusters 5 and 10 expressed TNF-α and IL-2, 
respectively (Figure 5F), similar to findings of tSNE analysis, 
but that all 3 clusters (ie, clusters 5, 10, and 2) expressed mac-
rophage inflammatory protein 1β (Figure 5F), confirming the 
results of tSNE analysis. The manual gating strategy also in-
dicated a trend toward decreased total population frequencies 
of CD14hiCD16- classical monocytes or increased total pop-
ulation frequencies of CD14-CD16+ nonclassical monocytes 
(Supplementary Figure 7B). Collectively, our results delineate 
the effect of metformin on the functional capacity of heteroge-
neous peripheral monocytes.
Metformin Enhances Innate Host Defense Pathways in Exposed Human 
Leukocytes
Metformin intake showed clear effects on innate host defense 
mechanisms. ROS production was strongly upregulated in 
whole-blood samples immediately after metformin treatment 
(Td6), both spontaneously and upon stimulation with M. tuber-
culosis lysate and zymosan (Figure 6A). In line with increased 
ROS production in whole-blood specimens, genes involved in 
ROS production, such as CYBB (which encodes NADPH ox-
idase 2), CYBA (which encodes p22-PHOX), RAC1 (which 
encodes Rac family small GTPase 1), and, particularly for ROS 
production in neutrophils, NCF1 (which encodes p47-PHOX), 
NCF2 (which encodes p67-PHOX), and NCF4 (which encodes 
p40-PHOX), were strongly upregulated in blood specimens 
after metformin intake (Figure 6B). The increase in ROS pro-
duction did not correlate with an increase in white blood cell 
or neutrophil counts (Supplementary Figure 8B and 8C). No 
increase in ROS production was observed in isolated PBMCs 
(Supplementary Figure 8A).
RNAseq analysis of whole-blood specimens revealed that 
metformin upregulated genes involved in endocytosis, such as 
receptors (RTKs and GPCR), regulators of clathrin-mediated 
pit formation (AP2) and clathrin uncoating (Hsp70), and regu-
lators of intracellular vesicular trafficking (Arfs, ArgGAPs, and 
ArfGEFs; Supplementary Figure 9A). Increased phagocytosis 
activity following metformin intake was confirmed in a second 
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group of healthy subjects taking metformin, using zymosan-la-
beled beads in whole-blood specimens (Figure 6C). The increase 
in phagocytosis activity correlated with an increase in white 
blood cell counts but not neutrophil counts (Supplementary 
Figure 9B). Furthermore, in vitro metformin-pretreated PBMCs 
also showed upregulated phagocytosis (Supplementary Figure 
9C). Finally, we examined the effect of metformin on the killing 
of M. tuberculosis. Of 8 subjects, metformin led to restricted ex 
vivo growth of M. tuberculosis in 4 subjects. Overall, there were 
no significant differences (Figure 6D). The colony-forming unit 
counts were unaffected by normalization to monocyte numbers.
DISCUSSION
A study in mice and retrospective human data suggest that 
metformin, the most widely used diabetes drug, may improve 
the outcome of tuberculosis [4, 6, 8]. We examined how met-
formin modulates the peripheral immune cell distribution, its 
gene expression, and its functional output in humans, using 
high-dimensional phenotypic and RNA analyses. Metformin 
administration was found to dampen proinflammatory cy-
tokine production while promoting phagocytosis and ROS 
production, possibly through the generation of nonclassical 
monocytes, which are implicated in trained innate immunity 
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Figure 5. Metformin intake in healthy volunteers alters the blood cellular composition landscape. A–C, Analysis of leukocyte counts plotted as raw cell counts for whole 
blood (A), as percentage of total counts for whole blood (B), and as percentage of total counts for isolated peripheral blood mononuclear cells (PBMCs; C). D, Cryopreserved 
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Figure 6. Metformin intake in healthy volunteers affects ex vivo antimycobacterial defense mechanisms but not Mycobacterium tuberculosis outgrowth. A, Reactive oxygen 
species (ROS) production, as measured by luminol reaction, in whole-blood specimens collected from volunteers before and after metformin treatment and stimulated with Roswell 
Park Memorial Institute medium (RPMI), M. tuberculosis lysate, or zymosan. Data are representative of 11 individual donors. Bars representing the fold change in production in spec-
imens collected on treatment day 6 (Td6), Td9, or Td21 over that in specimens collected on Td0 for each individual donor are superimposed with gray dots representing mean values 
± standard errors of the mean. B, Expression of 6 genes encoding key NADPH oxidase proteins for ROS production were assessed in ex vivo blood specimens by RNA sequencing 
analysis (RNAseq) before and after administration of metformin in the healthy volunteers. *P < .05 and **P < .01, by the Wilcoxon matched-pairs signed rank test. C, Net phago-
cytosis of pHrodo conjugates in healthy volunteers given metformin for 7 days. Upon RBC lysis, blood cells were incubated with the pHrodo suspension for 2 hours in an incubator 
without elevated CO2 levels at 37°C before measuring fluorescence. D, Numbers of colony-forming units (CFU) per milliliter after 24 hours or 48 hours of infection of peripheral blood 
mononuclear cells that were obtained from volunteers before and after metformin treatment and then infected with mycobacteria. Data were normalized to the monocyte count.
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[22]. These functional changes were associated with an inhibi-
tion of the type 1 IFN pathway, a decrease in p-AKT and p-P38 
signaling, and an increase in AMPK signaling. Our data are in 
line with increasing evidence that metformin possesses antiin-
flammatory properties, considered to be mediated in part via 
alterations in cellular metabolism [23].
A strong effect of metformin on inflammatory cytokine sig-
naling was observed both in vitro and in vivo. Metformin in-
hibited the type I  IFN response by blocking the expression of 
the IFN-stimulated genes IFIT1, IFIT2, and IFIT3, which among 
other activities, regulate inflammatory cytokine messenger RNA 
stability, cell proliferation, and apoptosis [24]. Neutrophil-driven 
type 1 IFN signaling in blood, including upregulated IFIT1, 
IFIT2, IFIT3, and genes similar to those in our data [25], but 
not type 1 IFNs themselves have been identified as a signature 
of active tuberculosis [26], and inhibiting this pathway by using 
zileuton, an arachidonic acid metabolism modulator, protects 
mice from tuberculosis [27]. Our data show that metformin can 
downregulate the type 1 interferon pathway in humans.
ROS production and phagocytosis activity were increased by 
metformin, and this was not explained by altered cell counts, 
suggesting that the observed effects are intrinsically mediated 
by metformin. This is supported by the accompanying tran-
scriptional changes observed in both ROS and phagocytosis-re-
lated genes and the increase in phagocytosis activity induced by 
metformin in vitro. Mechanistically, AMPK activation has been 
linked to phagocytosis activity as pharmacologic [28, 29] or ge-
netic [30, 31] ablation of AMPK subunits negatively influenced 
phagocytosis. It would be interesting to investigate the effect of 
metformin on autophagy in future studies and to compare this 
effect to findings from an elegant study showing that autophagic 
capacity does not correlate with M. tuberculosis susceptibility in 
mice [32]. As ours is the first exploratory study of the effects of 
metformin on host defense in vivo in nondiabetic individuals, 
future studies should examine the effect of metformin on the 
phagocytic capacity of specific cell types, such as macrophages 
and dendritic cells.
Metformin intake increased ex vivo mycobacterial killing 
capacity of PBMCs in some individuals but not all. In earlier 
work, we found that mycobacterial survival decreased in met-
formin-treated human macrophages [4]. This effect of met-
formin was reversed by the inclusion of ROS-scavenging agents. 
It is possible that 5 days of metformin exposure in vivo is too 
short, that the effect of metformin on killing capacity of PBMCs 
is somewhat lost during cryopreservation, or that other cells 
such as neutrophils contribute to the antimycobacterial effects 
of metformin. Future studies could use bronchiolar lavage cells 
to investigate control mechanisms from the disease site, rather 
than in peripheral blood. Alternatively, metformin could have 
subtle effects on mycobacterial killing and bigger effects on 
ameliorating inflammation. Whereas proinflammatory cyto-
kines are required for the control of M. tuberculosis, the balance 
between proinflammatory and antiinflammatory cytokines is 
important for the restriction of mycobacterial growth and pre-
vention of overt pathology [33, 34]. Here, we found that met-
formin dampens the expression of proinflammatory cytokines 
while enhancing antimycobacterial processes such as phagocy-
tosis and ROS production.
In mice, we have previously shown metformin-mediated re-
striction of M.  tuberculosis outgrowth [4], although another 
study found no additive effect of metformin when combined to 
the standard tuberculosis treatment [35]. In diabetic patients 
with tuberculosis, metformin use has been linked with more-
rapid culture conversion [9], particularly in patients with cav-
itary lung disease and a high bacterial burden [10], and with 
better treatment outcomes [9], indicating that the net result of 
all the effects of metformin is enhanced mycobacterial control 
in vivo. In a cohort of 296 diabetic patients with tuberculosis 
in Singapore [4], metformin was associated with lower mor-
tality, and a similar association was found in a cohort of 634 
diabetic patients in Taiwan [8]. However, neither cohort study 
included microbiological data. The survival difference could 
equally be explained by the well-known beneficial effects of 
metformin on cardiovascular mortality or by its immunomod-
ulating effects, as found in this study. Future clinical trials in 
nondiabetic patients with tuberculosis will help establish the 
effect of metformin on clinical and microbiological outcomes 
of tuberculosis treatment.
Metformin is put forward as a candidate for host-directed 
therapy of tuberculosis, but some caution is warranted. For 
example, in a model of candidemia, metformin resulted in 
increased lethality [36]. Also, it is unknown whether tubercu-
losis or concurrent use of antituberculous drugs increases the 
risk of metformin-associated gastrointestinal side effects or 
lactic acidosis [37]. With regard to possible drug interactions, 
a recent study in diabetic patients with tuberculosis has shown 
that rifampicin increases metformin exposure but does not alter 
blood glucose levels.
In summary, metformin effectively modulates the balance 
between inflammation and effective host responses to M. tuber-
culosis. It ameliorates the pathological inflammatory responses 
associated with tuberculosis while enhancing antimycobacterial 
processes such as ROS production and phagocytosis in humans.
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